The success of these two agents in pancreatic NETS supports the notion that targeting angiogenesis and/or PI3K/AKT/mTOR pathway is an important strategy for making therapeutic advances in this disease. This evidence concerns the gene AKT1 and pancreatic neuroendocrine tumor.